News

Media Contact

press@ampersand.bio

March 8, 2023

BioWorld

Ampersand Biomedicines set to develop programmable, more targeted therapeutics

Flagship Pioneering Inc. has unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable and effective by acting at the site of disease.

March 7, 2023

The Boston Globe

Flagship’s latest startup aims to develop drugs with fewer side effects

Ampersand Biomedicines launches with $50 million from the Cambridge firm to design medicines that better target the site of a disease than existing treatments.

March 7, 2023

Boston Business Journal

Flagship spins out $50M precision medicine startup

Flagship Pioneering is unveiling a new startup that takes aim at tricky-to-drug bodily targets by creating an "address map" of the human body.

March 7, 2023

Chemical & Engineering News

Flagship unveils latest brainchild: Ampersand Biomedicines

Flagship Pioneering has revealed yet another pharmaceutical start-up—Ampersand Biomedicines. With $50 million in funding, the newly launched company aims to design programmable, tissue-selective medicines.

March 7, 2023

Endpoints News

Ampersand snags $50M as Flagship focuses therapeutics on desired targets only

The behemoth biotech creator Flagship Pioneering is out with another startup aiming to achieve the crown jewel of drug development: treatments that hit only the desired target and cause no unwanted effects elsewhere.

March 7, 2023

BioPharma Dive

Flagship’s latest startup emerges with a plan for ‘smarter biologics’

Ampersand Biomedicines, a biotechnology startup focusing on what it calls programmable medicines, is emerging from stealth with $50 million in hand from Flagship Pioneering.

March 7, 2023

Fierce Biotech

Flagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity

Flagship Pioneering is back with a new biotech designed to tackle a key drug development challenge: on-target, off-tissue toxicity.

March 7, 2023

MedCity News

Flagship Startup Emerges With $50M to Send Drugs to the Right Biologic Address

Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.

March 7, 2023

BioCentury

Ampersand, Rapport launches reflect precision medicine trend

Ampersand Biomedicines, the latest company to emerge from Flagship Pioneering, is using its $50 million of funding to develop a platform for creating modular therapeutics that are localized to specific target tissues.